Down -8.52% in 4 Weeks, Here's Why Sarepta Therapeutics (SRPT) Looks Ripe for a Turnaround

Core Viewpoint - Sarepta Therapeutics (SRPT) has experienced significant selling pressure, resulting in an 8.5% decline in stock price over the past four weeks, but analysts anticipate better earnings than previously predicted, indicating potential for recovery [1]. Group 1: Technical Analysis - The Relative Strength Index (RSI) is utilized to identify oversold stocks, with a reading below 30 typically indicating oversold conditions [2]. - SRPT's current RSI reading is 29.78, suggesting that the heavy selling may be exhausting itself and a trend reversal could be imminent [5]. - The RSI serves as a momentum oscillator, helping investors identify potential entry points for stocks that have fallen below their fair value due to excessive selling pressure [3]. Group 2: Fundamental Analysis - Analysts have raised earnings estimates for SRPT by 10.1% over the last 30 days, indicating a strong consensus among sell-side analysts and suggesting potential price appreciation [6]. - SRPT holds a Zacks Rank 2 (Buy), placing it in the top 20% of over 4,000 ranked stocks based on earnings estimate revisions and EPS surprises, further supporting the stock's potential for a turnaround [7].